EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22

Seonghwan Hwang iD, Amy Hicks iD, Chai Zhen Hoo iD, Yong Seong Kwon iD, Ye Eun Cho iD, Joanna Moore iD, Bin Gao iD

Liver International · 2025-03 · 45 (3)

DOI: 10.1111/liv.15619 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 19.05.2023. Verfasst von Seonghwan Hwang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Interleukins, Acute-On-Chronic Liver Failure, Liver Failure, Acute. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Intramural Program of NIAAA, National Research Foundation of Korea Grant funded by the Korea Government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute liver failure (ALF) is a life‐threatening medical condition, characterized by rapidly progressive hepatic dysfunction, coagulopathy and hepatic encephalopathy in patients without chronic liver disease, while acute‐on‐chronic liver failure (ACLF) occurs in patients with existing chronic liver disease. ALF and ACLF are often associated with multiple organ failure and a high short‐term mortality. In this review, we briefly discuss the causes and pathogenesis of ALF and ACLF, the current options available for the treatment of both deadly maladies and interleukin‐22 (IL‐22), a novel promising drug that may have great therapeutic potential for ALF and ACLF treatment. IL‐22 is a cytokine produced by immune cells but mainly targets epithelial cells including hepatocytes. IL‐22 has been shown to protect against organ damage and reduce bacterial infection in many preclinical models and several clinical trials including alcohol‐associated hepatitis. The potential application of IL‐22 for the treatment of ALF and ACLF is also elaborated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InterleukinsAcute-On-Chronic Liver FailureLiver Failure, AcuteHumansInterleukin-22Animals

Stichwörter der Autor:innen

acute liver failureacute‐on‐chronic liver failureinterleukin‐22

Substanzen

InterleukinsInterleukin-22

Autor:innen und Institutionen

  • College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
  • Leeds Liver Unit, St James's University Hospital, Leeds, UK.
  • Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Seonghwan Hwang, Amy Hicks, Chai Zhen Hoo, Yong Seong Kwon, Ye Eun Cho, Joanna Moore, Bin Gao

Förderung

  • Intramural NIH HHS
  • Intramural Program of NIAAA
  • National Research Foundation of Korea Grant funded by the Korea Government (MSIT)

Zitieren

APA

Hwang, S., Hicks, A., Hoo, C. Z., Kwon, Y. S., Cho, Y. E., Moore, J., & Gao, B. (2025). Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22. Liver International, 45(3). https://doi.org/10.1111/liv.15619

Vancouver

Hwang S, Hicks A, Hoo CZ, Kwon YS, Cho YE, Moore J, et al. Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22. Liver International. 2025;45(3). doi:10.1111/liv.15619

BibTeX
@article{Hwang2025,
  author = {Hwang, Seonghwan and Hicks, Amy and Hoo, Chai Zhen and Kwon, Yong Seong and Cho, Ye Eun and Moore, Joanna and Gao, Bin},
  title = {Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1111/liv.15619}
}
Kostenlos starten →